Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

NCT01237327

Last updated date
Study Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, , 100021, China
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Previous participation in study 971-ONC-0028-080.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects who had not previously participated in study 971-ONC-0028-080.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic Breast CancerPalbociclib After CDK and Endocrine Therapy (PACE)
NCT03147287
  1. Boston, Massachusetts
  2. Miami, Florida
  3. Atlanta, Georgia
  4. Chicago, Illinois
  5. Indianapolis, Indiana
  6. Kansas City, Kansas
  7. Overland Park, Kansas
  8. Westwood, Kansas
  9. Louisville, Kentucky
  10. Bangor, Maine
  11. Boston, Massachusetts
  12. Brighton, Massachusetts
  13. Milford, Massachusetts
  14. Pittsfield, Massachusetts
  15. South Weymouth, Massachusetts
  16. Lee's Summit, Missouri
  17. Saint Louis, Missouri
  18. Londonderry, New Hampshire
  19. Chapel Hill, North Carolina
  20. Philadelphia, Pennsylvania
  21. Houston, Texas
  22. Milwaukee, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Breast CancerPAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011
  1. Paris,
  2. Villejuif,
Female
18 Years+
years
MULTIPLE SITES
Metastatic Breast CancerMulticenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
NCT01237327
  1. Beijing,
  2. Beijing,
  3. Nanjing,
  4. Nanjing,
  5. Shanghai,
  6. Tianjin,
  7. Xi'an,
Female
0+
years
MULTIPLE SITES
Metastatic Breast CancerA Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676
  1. Plainville, Connecticut
  2. Southington, Connecticut
  3. Boca Raton, Florida
  4. Plantation, Florida
  5. Berazategui, Buenos Aires
  6. Rosario, Santa FE
  7. San Miguel de Tucuman, Tucuman
  8. C.a.b.a,
  9. Fortaleza, CE
  10. Goiania, GO
  11. Curitiba, Parana
  12. Londrina, Parana
  13. Lajeado, RIO Grande DO SUL
  14. Ijui, RS
  15. Porto Alegre, RS
  16. Itajai, Santa Catarina
  17. Barretos, SAO Paulo
  18. Florianopolis, SC
  19. Itajai, SC
  20. Santo Andre, SP
  21. Santo Andre, SP
  22. Temuco, Region DE LA Araucania
  23. Temuco, Region DE LA Araucania
  24. Temuco, Region DE LA Araucania
  25. Temuco, Region DE LA Araucaniz
  26. Santiago, RM
  27. Vina del Mar, V Region
  28. Vina del Mar, V Region
  29. Temuco,
  30. V Region,
  31. V Region,
  32. Praha 2,
  33. Chania, Crete
  34. Pylaia, Thessaloniki
  35. Athens,
  36. Kecskemet,
  37. Miskolc,
  38. Szolnok,
  39. Szombathely,
  40. Visakhapatnam, Andhra Pradesh
  41. Bengaluru, Karnataka
  42. Manipal, Karnataka
  43. Mumbai, Maharashtra
  44. Nashik, Maharashtra
  45. Navi Mumbai, Maharashtra
  46. Pune, Maharashtra
  47. Pune, Maharashtra
  48. Pune, Maharashtra
  49. Cuttack, Odisha
  50. Bikaner, Rajasthan
  51. Madurai, Tamil NADU
  52. Hyderabad, Telangana
  53. Nagoya, Aichi
  54. Fukuoka-Shi, Fukuoka
  55. Kurume-city, Fukuoka
  56. Sapporo, Hokkaido
  57. Kumamoto-city, Kumamoto
  58. Kitaadachi-gun, Saitama
  59. Bunkyo-ku, Tokyo
  60. Meguro-Ku, Tokyo
  61. Shinagawa-ku, Tokyo
  62. Chiba,
  63. Kagoshima,
  64. Niigata,
  65. Osaka,
  66. Osaka,
  67. Shizuoka,
  68. Cheongju-si, Chungcheongbuk-do
  69. Ulsan, Korea
  70. Busan,
  71. Daegu,
  72. Goyang-si,
  73. Seoul,
  74. Seoul,
  75. Seoul,
  76. Riga,
  77. Mexico City, Distrito Federal
  78. Mexico, Distrito Federal
  79. Mexico, Distrito Federal
  80. Oaxaca,
  81. Queretaro,
  82. Lima,
  83. Lima,
  84. Lima,
  85. Lima,
  86. Lima,
  87. Lima,
  88. Lima,
  89. Lima,
  90. Lima,
  91. Lima,
  92. Cebu City, Cebu
  93. San Juan City, Mentro Manila
  94. Manila, Metro Manila
  95. Quezon City, Metro Manila
  96. Manila, NCR
  97. Pasig City, NCR
  98. Quezon City, NCR
  99. Cebu City, Region VII
  100. Manila,
  101. Gdansk,
  102. Gdynia,
  103. Lodz,
  104. Olsztyn,
  105. Rzeszow,
  106. Warszawa,
  107. Braga,
  108. Lisboa,
  109. Cluj-Napoca, Cluj
  110. Cluj-Napoca, Cluj
  111. Craiova, Dolj
  112. Craiova, Jud Dolj
  113. Bucuresti,
  114. Sibiu,
  115. Suceava,
  116. Timisoara,
  117. Grozny, Chechenkaya Republic
  118. Kislino Settlement, Kursk
  119. Kuzmolovo, Vsevolozhskiy, Leningrad Region
  120. Saint-Petersburg, Pos.pesochny
  121. Saint-Petersburg, Poselok Pescochny
  122. Ufa, Republic OF Bashkortostan
  123. Ufa, Republic OF Baskortostan
  124. Ufa, Republic OF Baskortostan
  125. Petrozavodsk, Republic OF Karelia
  126. Saransk, Republic OF Mordovia
  127. Rostov-on-Don, Rostov Region
  128. Pushkin, Saint Petersburg
  129. Pesochniy, Saint-petersburg
  130. Poselok Pesochny, Saint-petersburg
  131. Kislovodsk, Stavropol Region
  132. Lermomtov, Stavropol Region
  133. Pyatigorsk, Stavropol Region
  134. Pyatigorsk, Stavropol Region
  135. Pyatigorsk, Stavropol Region
  136. Pyatigorsk, Stavropol Region
  137. Pyatigorsk, Stavropol Region
  138. Volzhskiy, Volgograd Region
  139. Volzhskiy, Volgograd Region
  140. Volzhskiy, Volgograd Region
  141. Arkhangelsk,
  142. Chelyabinsk,
  143. Chelyabinsk,
  144. Ivanovo,
  145. Kaluga,
  146. Magnitogorsk,
  147. Moscow,
  148. Moscow,
  149. Moscow,
  150. Moscow,
  151. Nizhniy Novgorod,
  152. Nizhniy Novgorod,
  153. Nizhniy Novgorod,
  154. Nizhniy Novgorod,
  155. Omsk,
  156. Orel,
  157. Perm,
  158. Petrozavodsk,
  159. Ryazan,
  160. Saint Petersburg,,
  161. Saint Petersburg,
  162. Saint Petersburg,
  163. Saint Petersburg,
  164. Saint Petersburg,
  165. Saint-Petersburg,
  166. Saint-Petersburg,
  167. Saint-Petersburg,
  168. Saint-Petersburg,
  169. Saint-Petersburg,
  170. Saratov,
  171. Saratov,
  172. Stavropol,
  173. Volgograd,
  174. Volzhskiy,
  175. Belgrade,
  176. Belgrade,
  177. Nis,
  178. Sremska Kamenica,
  179. Bratislava,
  180. Bratislava,
  181. Port Elizabeth, Eastern CAPE
  182. Johannesburg, Gauteng
  183. Johannesburg, Gauteng
  184. Johannesburg, Gauteng
  185. Johannesburg, Gauteng
  186. Johannesburg, Gauteng
  187. Johannesburg, Gauteng
  188. Johannesburg, Gauteng
  189. Johannesburg, Gauteng
  190. Johannesburg, Gauteng
  191. Johannesburg, Gauteng
  192. Johannesburg, Gauteng
  193. Johannesburg, Gauteng
  194. Parktown, Gauteng
  195. Pretoria, Gauteng
  196. Pretoria, Gauteng
  197. Cape Town, Western CAPE
  198. Cape Town, Western CAPE
  199. Cape Town, Western CAPE
  200. Kraaifontein, Western CAPE
  201. Parow, Western CAPE
  202. Rondebosch, Western CAPE
  203. Bangkapi, Bangkok
  204. Jatujak, Bangkok
  205. Jatujak, Bangkok
  206. Ratchathewi, Bangkok
  207. Suanluang, Bangkok
  208. Muang, Kanchanaburi
  209. Muang, Nonthaburi
  210. Amphur Muang, Udonthani
  211. Bangkok,
  212. Khon Khaen,
  213. Udonthani,
  214. Adana,
  215. Ankara,
  216. Bursa,
  217. Diyarbakir,
  218. Gaziantep,
  219. Istanbul,
  220. Chernivtsi,
  221. Dnipropetrovsk,
  222. Kharkiv,
  223. Kharkiv,
  224. Khmelnytskyi,
  225. Kryvyi Rih,
  226. Kyiv,
  227. Lviv,
  228. Odesa,
  229. Uzhgorod,
  230. Vinnytsia,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Official Title  ICMJE Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
Brief Summary Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Megestrol acetate
    Megestrol Acetate 160 mg oral tablets Qd
    Other Name: Megace
  • Drug: exemestane (Aromasin)
    exemestane (Aromasin) 25 mg oral tablets Qd
    Other Name: Aromasin
Study Arms  ICMJE
  • Active Comparator: 1
    Intervention: Drug: Megestrol acetate
  • Experimental: 2
    Intervention: Drug: exemestane (Aromasin)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 5, 2010)
84
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2009
Actual Primary Completion Date December 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Previous participation in study 971-ONC-0028-080.

Exclusion Criteria:

  • Subjects who had not previously participated in study 971-ONC-0028-080.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01237327
Other Study ID Numbers  ICMJE 971-ONC-0028-094
A5991027
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP